Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer

Naomi R.M. Schwartz,Meghan R. Flanagan,Joseph B. Babigumira,Lotte M. G. Steuten,Joshua A. Roth

Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer

2019

Naomi R.M. Schwartz
Meghan R. Flanagan
Joseph B. Babigumira
Lotte M. G. Steuten
Joshua A. Roth

BACKGROUND: Disease-free survival (DFS) in early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer is significantly greater with the addition of neratinib after adjuvant ...

Keywords:

Physical therapy
Human Epidermal Growth Factor Receptor 2
Oncology
Cost-effectiveness analysis
Trastuzumab
HER2 Positive Breast Cancer
Adjuvant
Medicine
Neratinib
Internal medicine
Breast cancer
disease free survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations